As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.

Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.

Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification.

Two different antibody-drug conjugates (ADCs) targeting the same protein produced remarkably similar phase 3 results in relapsed small-cell lung cancer (SCLC) at WCLC 2026. Hansoh Pharma’s risvutatug ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...